Search

Your search keyword '"Migone TS"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Migone TS" Remove constraint Author: "Migone TS" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
44 results on '"Migone TS"'

Search Results

1. Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys

2. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.

3. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.

4. Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.

5. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies.

6. Added benefit of raxibacumab to antibiotic treatment of inhalational anthrax.

7. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation.

8. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.

9. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

10. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

11. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.

12. Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivo.

13. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

14. Anthrax lethal and edema toxins produce different patterns of cardiovascular and renal dysfunction and synergistically decrease survival in canines.

15. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.

16. G alpha q-containing G proteins regulate B cell selection and survival and are required to prevent B cell-dependent autoimmunity.

17. B-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.

18. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact.

19. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.

20. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection.

21. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

22. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels.

23. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.

24. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

25. TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model.

26. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

27. The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal.

28. BLyS BINDS TO B CELLS WITH HIGH AFFINITY AND INDUCES ACTIVATION OF THE TRANSCRIPTION FACTORS NF-kappaB AND ELF-1.

29. Synthesis and release of B-lymphocyte stimulator from myeloid cells.

30. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS.

31. CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling.

32. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.

33. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.

34. Functional cooperation of the interleukin-2 receptor beta chain and Jak1 in phosphatidylinositol 3-kinase recruitment and phosphorylation.

35. Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.

36. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells.

37. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins.

38. Interleukin-2 (IL-2)-mediated induction of the IL-2 receptor alpha chain gene. Critical role of two functionally redundant tyrosine residues in the IL-2 receptor beta chain cytoplasmic domain and suggestion that these residues mediate more than Stat5 activation.

39. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway.

40. Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation.

41. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

42. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

43. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.

44. An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Catalog

Books, media, physical & digital resources